After investing at least $4.4 million in the genetic screening company 23andMe in 2007, Google is also putting money into a second Silicon Valley DNA-screening startup, Navigenics.

For $2,500, Navigenics gives customers their genetic likelihood for 18 medical conditions, from Alzheimer’s to rheumatoid arthritis to several types of cancer. Navigenics aims to boost disease prevention by providing customers reports on their DNA that they can share with their doctors. The company addresses privacy concerns by encrypting customer identities, and screens only for conditions for which there are scientifically sound genetic studies. The company also offers genetic counseling.